Corrigendum to ‘The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer’ [Journal of Thoracic Oncology, Volume 19 Issue 5 (2024) 786-802]

IF 20.8 1区 医学 Q1 ONCOLOGY Journal of Thoracic Oncology Pub Date : 2025-04-01 Epub Date: 2025-02-09 DOI:10.1016/j.jtho.2025.01.017
Kwun M. Fong M.B.B.S., PhD , Adam Rosenthal MS , Dorothy J. Giroux MS , Katherine K. Nishimura PhD, MPH , Jeremy Erasmus MD , Yolande Lievens MD, PhD , Mirella Marino MD , Edith M. Marom MD , Paul Martin Putora MD, PhD , Navneet Singh MD, DM, FRCP , Francisco Suárez MD , Ramon Rami-Porta MD , Frank Detterbeck MD , Wilfried E.E. Eberhardt Priv.-Doz. ∗ , Hisao Asamura MD ∗ , Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Members of the Advisory Boards, and Participating Institutions of the Lung Cancer Domain
{"title":"Corrigendum to ‘The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer’ [Journal of Thoracic Oncology, Volume 19 Issue 5 (2024) 786-802]","authors":"Kwun M. Fong M.B.B.S., PhD , Adam Rosenthal MS , Dorothy J. Giroux MS , Katherine K. Nishimura PhD, MPH , Jeremy Erasmus MD , Yolande Lievens MD, PhD , Mirella Marino MD , Edith M. Marom MD , Paul Martin Putora MD, PhD , Navneet Singh MD, DM, FRCP , Francisco Suárez MD , Ramon Rami-Porta MD , Frank Detterbeck MD , Wilfried E.E. Eberhardt Priv.-Doz. ∗ , Hisao Asamura MD ∗ , Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Members of the Advisory Boards, and Participating Institutions of the Lung Cancer Domain","doi":"10.1016/j.jtho.2025.01.017","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page 531"},"PeriodicalIF":20.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425000504","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
国际肺癌分期项目研究协会的勘误表:即将出版的肺癌TNM分类第九版中M描述符的修订建议[Journal of Thoracic Oncology, vol . 19 Issue 5(2024) 786-802]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Thoracic Oncology
Journal of Thoracic Oncology 医学-呼吸系统
CiteScore
36.00
自引率
3.90%
发文量
1406
审稿时长
13 days
期刊介绍: Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
期刊最新文献
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9th Edition Staging Database. First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and PD-L1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial. Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1